Home > Dermatology > EADV 2020 > Late-Breaking News > Efficacious non-steroidal topical for psoriasis

Efficacious non-steroidal topical for psoriasis

Presented By
Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA
Conference
EADV 2020
Trial
Phase 3, PSOARING
Once-daily tapinarof 1% cream has shown highly significant treatment success in a substantial proportion of psoriasis patients in the identical, multicentre, phase 3 PSOARING 1 and PSOARING 2 trials. “In psoriasis, we have a significant need for effective topical therapies that do not restrict the amount of time we can apply them or the locations on the body where we can apply them,” stated Prof. Mark Lebwohl (Icahn School of Medicine at Mount Sinai, USA) [1]. He referred to restrictions of high-potent topical corticosteroids that cannot be used, for example, in the face or intertriginous sites. Tapinarof is a first-in-class, non-steroidal topical aryl hydrocarbon receptor-modulating agent, which moderates pro-inflammatory pathways implicated in psoriasis (i.e. IL-17A, IL-17F) and atopic dermatitis (i.e. IL-4, IL-5, IL-13). “Tapinarof enters the cell where it binds to the aryl hydrocarbon receptor. That complex then enters the nucleus where it joins...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on